What is the recommended intravenous migraine cocktail (including drugs, dosages, and administration guidelines) for acute migraine treatment?

IV Migraine Cocktail for Acute Treatment

For adults presenting to the emergency department with acute migraine requiring parenteral therapy, administer IV prochlorperazine 10 mg with diphenhydramine 25 mg as first-line treatment, or IV metoclopramide 10-20 mg with diphenhydramine 25 mg as an equally effective alternative.

First-Line IV Regimens

The most strongly supported "migraine cocktail" combinations based on multiple high-quality trials include:

Dopamine Antagonist + Antihistamine (Primary Recommendation)

• Prochlorperazine 10 mg IV over 15 minutes + Diphenhydramine 25 mg IV 1, 2

  • Must be offered (Level A evidence) 2
  • Efficacy: 74% pain relief at 2 hours 3
  • Diphenhydramine prevents dystonic reactions

• Metoclopramide 10-20 mg IV over 15 minutes + Diphenhydramine 25 mg IV 4, 1, 2

  • Should be offered (Level B evidence) 2
  • Efficacy: 70% pain relief at 2 hours 3
  • Also treats nausea and improves gastric motility 4

Both regimens are equally effective - the choice between prochlorperazine and metoclopramide can be based on availability and patient preference, as 73-77% of patients want the same medication for future visits 3.

Alternative IV Options

NSAIDs (when dopamine antagonists contraindicated):

• Ketorolac 60 mg IV - should be offered (Level B) 2
• Dexketoprofen IV - highly likely effective 2
• Maximum 5 days treatment to avoid rebound 4

Migraine-Specific Agents:

• Sumatriptan 6 mg SC (not IV, but parenteral) - highly likely effective 2
• Reaches peak concentration in 15 minutes 4
• Contraindicated in cardiovascular disease, uncontrolled hypertension 4

Adjunctive Therapy for Recurrence Prevention

Add Dexamethasone 10-24 mg IV to prevent headache recurrence within 24-72 hours (Level B - should offer) 1, 2

Medications to Avoid

Must NOT offer:

• Hydromorphone IV - proven ineffective and high abuse potential 2
• Morphine IV - lack of efficacy evidence, concern for dependence 1

May NOT offer:

• Paracetamol (Acetaminophen) IV - likely ineffective 2

Administration Protocol

1. Assess for contraindications to dopamine antagonists (Parkinson's disease, seizure disorder, GI bleeding/obstruction, pheochromocytoma) 4

2. Administer antiemetic first when using dopamine antagonists:

   • Give diphenhydramine 25 mg IV before or with the dopamine antagonist 4, 3
   • This prevents dystonic reactions (restlessness, muscle weakness, dystonia) 4

3. Infuse slowly over 15 minutes to minimize adverse effects 3

4. Monitor for adverse events:

   • Hypotension, tachycardia, arrhythmias with prochlorperazine 4
   • Drowsiness, restlessness with metoclopramide 4
   • Arm pain at injection site (most common) 5

5. Reassess pain at 30-minute intervals for 2 hours using numeric rating scale 3

Clinical Decision Algorithm

Step 1: Patient presents with acute migraine requiring IV therapy

Step 2: Check for cardiovascular contraindications

• If present → Use dopamine antagonist regimen
• If absent → Either dopamine antagonist OR sumatriptan SC acceptable

Step 3: Select dopamine antagonist

• Prochlorperazine 10 mg IV (slightly higher efficacy) OR
• Metoclopramide 10-20 mg IV (also treats nausea)
• Always add diphenhydramine 25 mg IV

Step 4: Add dexamethasone 10-24 mg IV to prevent recurrence 1

Step 5: If inadequate response at 1 hour, consider:

• Ketorolac 60 mg IV 2
• Greater occipital nerve block (highly likely effective) 2

Important Caveats

Avoid medication overuse: Limit acute treatment to no more than 2 times per week to prevent medication-overuse headache 6. If patients require more frequent treatment, initiate preventive therapy.

Non-oral route essential when nausea/vomiting present early in attack 6. Oral medications have impaired absorption due to gastroparesis during migraine 4.

Opioids are NOT first-line: Despite common use, evidence supports avoiding opioids due to lack of efficacy data, abuse potential, and risk of medication-overuse headache 1, 2.

Newer evidence supersedes older guidelines: The 2025 AHS guideline 2 provides the most current Level A recommendation for prochlorperazine, upgrading it from the 2016 guideline's Level B recommendation 1.